---
title: "MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292765644.md"
description: "On July 15, 2026, MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Tokyo Stock Exchange (Code Number: 4875), disclosed that they have successfully reached the target enrollment of 200 patients in the SEANOBI-ALS study. This study, also known as Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers in ALS (NCT 06743776), is investigating the efficacy of MN-166 (ibudilast) in individuals with amyotrophic lateral sclerosis (ALS)."
datetime: "2026-07-15T12:02:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292765644.md)
  - [en](https://longbridge.com/en/news/292765644.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292765644.md)
generator: "portal-rs"
---

# MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

On July 15, 2026, MediciNova, Inc., a biopharmaceutical company listed on the NASDAQ Global Market (NASDAQ: MNOV) and the Tokyo Stock Exchange (Code Number: 4875), disclosed that they have successfully reached the target enrollment of 200 patients in the SEANOBI-ALS study. This study, also known as Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers in ALS (NCT 06743776), is investigating the efficacy of MN-166 (ibudilast) in individuals with amyotrophic lateral sclerosis (ALS).

### Related Stocks

- [4875.JP](https://longbridge.com/en/quote/4875.JP.md)
- [MNOV.US](https://longbridge.com/en/quote/MNOV.US.md)

## Related News & Research

- [ZV: 2025 revenues reached €596 million, with strong ESG performance and global market presence](https://longbridge.com/en/news/299008470.md)
- [This AI assistant bought me whey protein and booked a cabin for my birthday](https://longbridge.com/en/news/298353889.md)
- [Precise Biometrics Extends IOTRUST Partnership for Next-Gen DCENT Crypto Wallets](https://longbridge.com/en/news/299006377.md)
- [Live Nation report finds 93% of fans prefer real-world experiences over digital](https://longbridge.com/en/news/298922668.md)
- [IOVA: Strong sales growth, expanding clinical pipeline, and operational efficiencies support long-term outlook](https://longbridge.com/en/news/298626037.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**